We are a science-driven global biotech company

Transforming Potential into Reality

Find out more

Pipeline

Latest News

Press Releases

2024.11.06

I-Mab Appoints Sean Fu, PhD, MBA, as Chief Executive Officer

ROCKVILLE, MD, November 6, 2024 – I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that Sean (Xi-Yong) Fu, PhD, MBA has been appointed as the Company’s permanent Chief Executive Officer (“CEO”) effective November 1, 2024. Dr. Fu […]

2024.10.31

I-Mab to Release Q3 2024 Financial Results on November 14, 2024

ROCKVILLE, MD, October 31, 2024 – I-Mab (NASDAQ: IMAB) (the “Company”), a US-based, global biotech company, exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced that it plans to release financial results for the third quarter ended September 30, 2024, on Thursday, November 14, 2024, pre-market Eastern Time. […]

2024.10.30

I-Mab to Present Givastomig Phase 1 Optimal Dose Estimation Data at SITC 2024

– Poster to be presented in a late-breaking abstract session at the Society for Immunotherapy of Cancer (SITC) on Saturday, November 9, 2024 ROCKVILLE, MD, October 30, 2024 – I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company exclusively focused on the development of highly differentiated immunotherapies for the treatment of cancer, today announced […]

Our Purposeful Journey to Bring Innovative Medicines to People We Serve

Founded

I-Mab was established in June 2016

Series A Financing

I-Mab completed Series A financing, raising $58 million

Merger & Series B Financing

Third Venture Biopharma and Tasgen merged to form I-Mab, raising $120 million in Series B Financing

Series C Financing

I-Mab successfully raised $227 million in Series C Financing

Nasdaq Listing

I-Mab was listed on the Nasdaq Global Market as a clinical-stage biotech company

AbbVie Global Partnership

I-Mab and AbbVie enter into global strategic partnership on development and commercialization of I-Mab's novel CD47 monoclonal antibody lemzoparlimab

Private Placement with Hillhouse Capital-Led Consortium

I-Mab entered into $523 million private placement agreement with Hillhouse Capital-led consortium

Global Footprint

I-Mab established its global footprint with 9 locations, including new R&D site in San Diego, and new GMP facility in Hangzhou

Jumpcan Partnership

I-Mab and Jumpcan entered into a strategic partnership for commercialization of I-Mab’s highly differentiated long-acting recombinant human growth hormone, eftansomatropin alfa in mainland China

U.S.-Based Biotech

I-Mab signed agreement to divest its assets and business operations in China, bringing a greater focus on the U.S. and ex-China markets